NCT05073250 2023-05-12
IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.
Chinese PLA General Hospital
Phase 2 Unknown
Clinical Trials
13 trialsNCT04989621 2022-03-24
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
Sun Yat-sen University
Phase 2 Unknown
NCT02423837 2015-04-22
BRiF
National Research Center for Hematology, Russia
Phase 3 Unknown
NCT00258336 2014-01-10
Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01307592 2014-01-10
Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00005959 2013-12-04
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00028717 2013-09-17
Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00893477 2013-08-02
GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00896519 2013-08-02
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00397800 2012-08-28
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma
Technical University of Munich
Phase 1/2 Unknown
NCT00772655 2012-08-02
Zevalin® First Line in Follicular Lymphoma
Charite University, Berlin, Germany
Phase 2 Unknown
NCT00069966 2009-07-07
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00435955 2007-02-16
Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma
Azienda Ospedaliera San Giovanni Battista
Phase 3 Unknown